AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02974803
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
Trial: NCT02974803
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 2 mg once daily until progression or unaccepted toxicity.
Trial: NCT00121290
Drug: SJG-136
RxNorm normalized name: SJG-136
DrugBank: SJG-136 (DB11965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02263378
Drug: ellagic acid + annona muricata
RxNorm normalized name: Ellagic acid
DrugBank: Ellagic acid (DB08846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pills
Trial: NCT00003896
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003896
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01465152
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally before the three main meals for 24 weeks
Trial: NCT00316329
Drug: Artesunate + Amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02858024
Drug: Dapivirine Vaginal Ring-004 and no tampons
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
Trial: NCT02858024
Drug: Dapivirine Vaginal Ring-004 with tampons
RxNorm normalized name: vaginal ring with progestogen
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
Trial: NCT02858024
Drug: Dapivirine Vaginal Ring-004 with no menses
RxNorm normalized name: vaginal ring with progestogen
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
Trial: NCT02858024
Drug: Dapivirine Vaginal Ring-004 and same ring inserted after menses
RxNorm normalized name: miconazole
DrugBank: Dapivirine (DB08639)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
Trial: NCT02858024
Drug: Dapivirine Vaginal Ring-004 and new ring inserted after menses
RxNorm normalized name: vaginal ring with progestogen and estrogen
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
Trial: NCT04127396
Drug: Lenvatinib Pill
RxNorm normalized name: lenvatinib Pill
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
Trial: NCT04127396
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
Trial: NCT01998347
Drug: Paclitaxel liposome
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01998347
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01998347
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00944632
Drug: ZK 245186
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily topical non-occlusive application for up to 4 weeks
Trial: NCT03932916
Drug: Donepezil Pamoate for Injection 17mg
RxNorm normalized name: Triptorelin Pamoate for Injectable Suspension
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
Trial: NCT03932916
Drug: Donepezil Pamoate for Injection 34mg
RxNorm normalized name: Triptorelin Pamoate for Injectable Suspension
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
Trial: NCT03932916
Drug: Donepezil Hydrochloride 5mg
RxNorm normalized name: DONEPEZIL HYDROCHLORIDE 5MG/DAY PATCH
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A tablet of 5mg Donepezil Hydrochloride will be administered once.
Trial: NCT02888275
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01421992
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Tablet of methylphenidate, 20 mg per day during 3 weeks
Trial: NCT02966821
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
Trial: NCT02008006
Drug: BeEAM
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0
Trial: NCT03472521
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
Trial: NCT01603407
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
Trial: NCT01603407
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
Trial: NCT01603407
Drug: Deflazacort
RxNorm normalized name: Deflazacort
DrugBank: Deflazacort (DB11921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
Trial: NCT02614508
Drug: Buparlisib
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02614508
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04129294
Drug: NS-089/NCNP-02
DrugBank: Brogidirsen (DB18884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks.
Trial: NCT01607346
Drug: ezogabine/retigabine
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
Trial: NCT00343655
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02076815
Drug: Anagrelide retard
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
Trial: NCT00309023
Drug: BMS-663513
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
Trial: NCT04229771
Drug: Balanced salt solution
RxNorm normalized name: Balanced Salt Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop instilled in one eye, randomly chosen, as control placebo
Trial: NCT01476800
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00625183
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01605825
Drug: placebo/dalfampridine-ER
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Trial: NCT01429441
Drug: Ocriplasmin
RxNorm normalized name: Ocriplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.125 mg single intravitreal injection
Trial: NCT00715871
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study.
Trial: NCT00094523
Drug: Fosamprenavir
RxNorm normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosamprenavir
Trial: NCT00042653
Drug: AMG 073
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
Trial: NCT00844662
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet 800mg
Trial: NCT01990768
Drug: 1 gram Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Trial: NCT01990768
Drug: 0.9% Sodium Chloride injectable
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
Trial: NCT02145637
Drug: Afatinib plus Ruxolitinib combination therapy
RxNorm normalized name: Afatinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04539548
Drug: Prednisolone acetate ophthalmic suspension USP 1%
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week
Trial: NCT01857804
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
Trial: NCT01857804
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
Trial: NCT01857804
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
Trial: NCT01153009
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated vortioxetine immediate release tablets
Trial: NCT01153009
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overencapsulated duloxetine delayed-release capsules
Trial: NCT00401193
Drug: Tranexamic acid tablets
RxNorm normalized name: Tranexamic Acid Tablets
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3900 mg/Day
Trial: NCT00401193
Drug: Tranexamic acid tablets
RxNorm normalized name: Tranexamic Acid Tablets
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1950 mg/Day
Trial: NCT01856998
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01856998
Drug: Diprivan
RxNorm normalized name: Diprivan
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00116636
Drug: Kaletra
RxNorm normalized name: Kaletra
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00441363
Drug: Bromocriptine Mesylate
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8 mg tablet
Trial: NCT01971515
Drug: MSC2363318A
RxNorm normalized name: MSC2363318A
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).
Trial: NCT01971515
Drug: MSC2363318A plus Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion.
Trial: NCT01048944
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
Trial: NCT01048944
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
Trial: NCT03250338
Drug: Crenolanib
RxNorm normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenolanib will be administered orally
Trial: NCT03250338
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HAM regimen~FLAG-Ida
Trial: NCT03250338
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HAM regimen
Trial: NCT03250338
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG-Ida regimen
Trial: NCT03250338
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FLAG-Ida regimen
Trial: NCT03250338
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FLAG-Ida regimen
Trial: NCT00528359
Drug: quetiapine or olanzapine or risperidone or aripiprazole
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02660684
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection or oral
Trial: NCT02660684
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection or oral
Trial: NCT00399711
Drug: repaglinide and metformin combination tablet
RxNorm normalized name: metformin and repaglinide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00399711
Drug: rosiglitazone and metformin combination tablet
RxNorm normalized name: metformin and rosiglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01613079
Drug: Tripterygium wilfordii Hook F
RxNorm normalized name: Tripterygium wilfordii whole extract
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Trial: NCT00910117
Drug: nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimotuzumab 400 mg d1
Trial: NCT02802696
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
Trial: NCT02425462
Drug: Dienogest (Visanne, BAY86-5258)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest 2mg daily Oral dose
Trial: NCT02157571
Drug: Prulifloxacin
RxNorm normalized name: prulifloxacin
DrugBank: Prulifloxacin (DB11892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/tablet, oral administration of a single tablet.
Trial: NCT02157571
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg/tablet, oral administration of a tablet daily.
Trial: NCT02157571
Drug: Levofloxacin Placebo
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of levofloxacin hydrochloride tablet, without active components.
Trial: NCT02157571
Drug: Prulifloxacin placebo
DrugBank: Prulifloxacin (DB11892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of prulifloxacin film-coated tablet without active components.
Trial: NCT00171158
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02528617
Drug: Velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Enzyme replacement therapy
Trial: NCT01229319
Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
Trial: NCT02117219
Drug: VIDAZA
RxNorm normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
Trial: NCT03372382
Drug: Norco
RxNorm normalized name: Norco
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen plus opioid
Trial: NCT00488137
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg o.d.
Trial: NCT00488137
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg o.d.